Share on StockTwits
 

Myriad Genetics (NASDAQ:MYGN) Insider Peter D. Meldrum sold 123,940 shares of the stock on the open market in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $31.10, for a total transaction of $3,854,534.00. Following the transaction, the insider now directly owns 55,656 shares in the company, valued at approximately $1,730,902. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Ladenburg Thalmann downgraded shares of Myriad Genetics from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. Separately, analysts at JMP Securities upgraded shares of Myriad Genetics from an “underperform” rating to a “market perform” rating in a research note to investors on Wednesday. They now have a $30.80 price target on the stock. Finally, analysts at Mizuho raised their price target on shares of Myriad Genetics from $24.00 to $28.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $27.27.

Myriad Genetics (NASDAQ:MYGN) traded up 15.12% during mid-day trading on Wednesday, hitting $31.29. The stock had a trading volume of 9,315,730 shares. Myriad Genetics has a 1-year low of $20.02 and a 1-year high of $38.27. The stock has a 50-day moving average of $24.49 and a 200-day moving average of $26.17. The company has a market cap of $2.339 billion and a P/E ratio of 13.02.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.20. The company had revenue of $204.06 million for the quarter, compared to the consensus estimate of $176.02 million. During the same quarter in the previous year, the company posted $0.42 earnings per share. The company’s revenue for the quarter was up 36.9% on a year-over-year basis. Analysts expect that Myriad Genetics will post $1.97 EPS for the current fiscal year.

Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.